Division of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Department of Clinical Pathology, Division of Laboratory Medicine, Skåne University Hospital, Lund, Sweden.
Sci Rep. 2019 Oct 29;9(1):15506. doi: 10.1038/s41598-019-51697-6.
High-grade serous ovarian cancer (HGSOC) is the most common subtype of epithelial ovarian cancer and early detection is challenging. TP53 mutations are a hallmark of HGSOC and detection of these mutations in liquid-based Pap samples could provide a method for early diagnosis. Here we evaluate the use of IBSAFE, an ultra-sensitive droplet digital PCR (ddPCR) method, for detecting TP53 mutations in liquid-based Pap samples collected from fifteen women at the time of diagnosis (diagnostic samples) and/or up to seven years prior to diagnosis (archival samples). We analysed tumours for somatic TP53 mutations with next generation sequencing and were able to detect the corresponding mutations in diagnostic samples from six of eight women, while one patient harboured a germline mutation. We further detected a mutation in an archival sample obtained 20 months prior to the ovarian cancer diagnosis. The custom designed IBSAFE assays detected minor allele frequencies (MAFs) with very high assay sensitivity (MAF = 0.0068%) and were successful despite low DNA abundance (0.17-206.14 ng, median: 17.27 ng). These results provide support for further evaluation of archival liquid-based Pap samples for diagnostic purposes and demonstrate that ultra-sensitive ddPCR should be evaluated for ovarian cancer screening in high-risk groups or in the recurrent setting.
高级别浆液性卵巢癌(HGSOC)是上皮性卵巢癌中最常见的亚型,早期检测具有挑战性。TP53 突变是 HGSOC 的标志,在基于液体的巴氏样本中检测这些突变可以提供早期诊断的方法。在这里,我们评估了 IBSAFE 的用途,IBSAFE 是一种超灵敏的液滴数字 PCR(ddPCR)方法,用于检测 15 名女性在诊断时(诊断样本)和/或诊断前长达七年(存档样本)收集的基于液体的巴氏样本中的 TP53 突变。我们使用下一代测序分析肿瘤中的体细胞 TP53 突变,并能够在 8 名女性中的 6 名的诊断样本中检测到相应的突变,而一名患者携带种系突变。我们还在卵巢癌诊断前 20 个月获得的存档样本中检测到一个突变。定制设计的 IBSAFE 检测方法检测到了非常高检测灵敏度(MAF=0.0068%)的小等位基因频率(MAF),尽管 DNA 丰度低(0.17-206.14ng,中位数:17.27ng),但检测仍取得了成功。这些结果为进一步评估存档液体巴氏样本的诊断目的提供了支持,并表明超灵敏 ddPCR 应在高危人群或复发人群中用于卵巢癌筛查进行评估。